Combination of immunosuppressive drugs and allogeneic stem cell treatment in a dog with suspected nephrotic syndrome

Jin Y, Son Y, Oh T, Bae S (2022): Combination of immunosuppressive drugs and allogeneic stem cell treatment in a dog with suspected nephrotic syndrome. Vet Med-Czech 67, 492–496.

download PDF

The case study aims to describe the nephrotic syndrome (NS) in a castrated 3-year-old male Cocker Spaniel dog. The patient arrived at the hospital with a loss of appetite and weakness. Skin oedema with ascites was observed along with hypoalbuminaemia, hypoproteinaemia, hyperlipidaemia, hypercholesterolaemia, and proteinuria (urine protein to creatinine ratio = 22.4). Based on these findings, the patient was diagnosed with NS, although a renal biopsy was not conducted. Prednisolone (1 mg/kg, p.o. q12 h) and mycophenolate mofetil (10 mg/kg, p.o. q12 h) were prescribed as the immunosuppressive drugs, and previously cryopreserved allogeneic adipose tissue-derived mesenchymal stem cells (2 × 107 cells/kg) were injected intravenously. After several weeks of treatment, the patient recovered from NS. This is the first case report on immunosuppressive drugs and allogeneic mesenchymal stem cells being used to treat a dog with NS.

Appel AS, Appel GB. An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol. 2009 Mar;5(3):132-42.
Banyard MRC, Hassett RS. The use of mycophenolate mofetil in the treatment of a case of immune-mediated glomerulonephritis in a dog. Aust Vet Pract. 2001 Sep;31(3):103-6.
Bochon B, Kozubska M, Surygala G, Witkowska A, Kuzniewicz R, Grzeszczak W, Wystrychowski G. Mesenchymal stem cells – Potential applications in kidney diseases. Int J Mol Sci. 2019 May 18;20(10):2462.
Center SA, Smith CA, Wilkinson E, Erb HN, Lewis RM. Clinicopathologic, renal immunofluorescent, and light microscopic features of glomerulonephritis in the dog: 41 cases (1975–1985). J Am Vet Med Assoc. 1987 Jan 1;190(1):81-90.
Dias IE, Pinto PO, Barros LC, Viegas CA, Dias IR, Carvalho PP. Mesenchymal stem cells therapy in companion animals: Useful for immune-mediated diseases? BMC Vet Res. 2019 Oct 22;15(1):358.
Klosterman E, Moore G, de Brito Galvao J, DiBartola S, Groman R, Whittemore J, Vaden S, Harris T, Byron J, Dowling S. Comparison of signalment, clinicopathologic findings, histologic diagnosis, and prognosis in dogs with glomerular disease with or without nephrotic syndrome. J Vet Intern Med. 2011 Mar-Apr;25(2):206-14.
Klosterman ES, Pressler BM. Nephrotic syndrome in dogs: Clinical features and evidence-based treatment considerations. Top Companion Anim Med. 2011 Aug;26(3):135-42.
Kode JA, Mukherjee S, Joglekar MV, Hardikar AA. Mesenchymal stem cells: Immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy. 2009 Jan;11(4):377-91.
Kronenberg F. Dyslipidemia and nephrotic syndrome: Recent advances. J Ren Nutr. 2005 Apr;15(2):195-203.
Lee SJ, Ryu MO, Seo MS, Park SB, Ahn JO, Han SM, Kang KS, Bhang DH, Youn HY. Mesenchymal stem cells contribute to improvement of renal function in a canine kidney injury model. In Vivo. 2017 Nov-Dec;31(6):1115-24.
Lee HK, Kim KH, Kim HS, Kim JS, Lee JH, Ji A, Kim KS, Lee TY, Chang IY, Bae SC, Hong JT, Kim YS, Han SB. Effect of a combination of prednisone or mycophenolate mofetil and mesenchymal stem cells on lupus symptoms in MRL.Fas1pr mice. Stem Cells Int. 2018 Jul 3;2018:4273107.
Lukomska B, Stanaszek L, Zuba-Surma E, Legosz P, Sarzynska S, Drela K. Challenges and controversies in human mesenchymal stem cell therapy. Stem Cells Int. 2019 Apr 9;2019:9628536.
Peired AJ, Sisti A, Romagnani P. Mesenchymal stem cell-based therapy for kidney disease: A review of clinical evidence. Stem Cells Int. 2016 Sep;2016:4798639.
Perez-Merino EM, Uson-Casaus JM, Duque-Carrasco J, Zaragoza-Bayle C, Marinas-Pardo L, Hermida-Prieto M, Vilafranca-Compte M, Barrera-Chacon R, Gualtieri M. Safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells for treatment of dogs with inflammatory bowel disease: Endoscopic and histological outcomes. Vet J. 2015 Dec;206(3):391-7.
Pittenger MF, Discher DE, Peault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019 Dec 2;4:1-15.
Pressler B, Vaden S, Gerber B, Langston C, Polzin D. Consensus guidelines for immunosuppressive treatment of dogs with glomerular disease absent a pathologic diagnosis. J Vet Intern Med. 2013 Nov-Dec;27(Suppl_1):S55-9.
Quimby JM, Webb TL, Habenicht LM, Dow SW. Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: Results of three sequential pilot studies. Stem Cell Res Ther. 2013 Apr 30;4(2):1-12.
Schneider N, Goncalves Fda C, Pinto FO, Lopez PL, Araujo AB, Pfaffenseller B, Passos EP, Cirne-Lima EO, Meurer L, Lamers ML, Paz AH. Dexamethasone and azathioprine promote cytoskeletal changes and affect mesenchymal stem cell migratory behavior. PLoS One. 2015 Mar 10;10(3):e0120538.
Segev G, Cowgill LD, Heiene R, Labato MA, Polzin DJ. Consensus recommendations for immunosuppressive treatment of dogs with glomerular disease based on established pathology. J Vet Intern Med. 2013 Nov-Dec;27(Suppl_1):S44-54.
Teng X, Chen L, Chen W, Yang J, Yang Z, Shen Z. Mesenchymal stem cell-derived exosomes improve the microenvironment of infarcted myocardium contributing to angiogenesis and anti-inflammation. Cell Physiol Biochem. 2015 Dec;37(6):2415-24.
van den Berg JG, Weening JJ. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin Sci (Lond). 2004 Aug;107(2):125-36.
download PDF

© 2022 Czech Academy of Agricultural Sciences | Prohlášení o přístupnosti